Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study

Andrew M. Tershakovec, William F. Keane, Zhongxin Zhang, Paulette A. Lyle, Gerald B. Appel, Janet B. McGill, Hans Henrik Parving, Mark E. Cooper, Shahnaz Shahinfar, Barry M. Brenner

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Renal pathology and dyslipidemia commonly coexist. Treatments that lower albuminuria/ proteinuria may lower lipids, but it is not known whether lipid lowering independent of lessening albuminuria/proteinuria slows progression of kidney disease. We examined the association between LDL cholesterol levels and treatment with losartan on end-stage renal disease (ESRD). Lipid levels and albuminuria measurements were obtained at baseline and at year 1 in a post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study, which compared the effects of losartan- versus placebobased antihypertensive therapy in patients with type 2 diabetes and nephropathy. LDL cholesterol lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria.

Original languageEnglish
Pages (from-to)445-447
Number of pages3
JournalDiabetes care
Volume31
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Dive into the research topics of 'Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study'. Together they form a unique fingerprint.

Cite this